The effects of potassium channel opener P1075 on the human saphenous vein and human internal mammary artery

Journal of Cardiovascular Pharmacology

Volumn 57, Issue 6, 2011, Pages 648-655

  Gojkovic Bukarica, Ljiljana C ^a,f   Beleslin Cokic, Bojana B ^a   Novakovic, Aleksandra N ^b   Peric, Miodrag S ^c   Markovic Lipkovski, Jasmina Z ^a   Cirovic, Sanja Z ^a   Nezic, Dusan G ^c   Lesic, Aleksandar R ^a   Kanjuh, Vladimir I ^d   Heinle, Helmut ^e  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c Institute for Cardiovascular Diseases Dedinje   (Serbia)

^d SERBIAN ACADEMY OF SCIENCES AND ARTS   (Serbia)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f NONE   (Serbia)

Author keywords

bypass grafts; electric field stimulation; immunomorphology; KATP channels; P1075

Indexed keywords

GLIBENCLAMIDE; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.1; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; NORADRENALIN; P1075; PHENYLEPHRINE; POTASSIUM CHANNEL STIMULATING AGENT; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ADULT; AGED; ARTERY CONSTRICTION; ARTERY GRAFT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ELECTROSTIMULATION; HUMAN; HUMAN TISSUE; INTERNAL MAMMARY ARTERY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SAPHENOUS VEIN; VASODILATATION;

AGED; ELECTRIC STIMULATION; GLYBURIDE; GUANIDINES; HUMANS; KATP CHANNELS; MALE; MAMMARY ARTERIES; MIDDLE AGED; ORGAN CULTURE TECHNIQUES; ORGAN SPECIFICITY; OSMOLAR CONCENTRATION; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; PROTEIN SUBUNITS; PYRIDINES; SAPHENOUS VEIN; VASOCONSTRICTION; VASODILATION; VASODILATOR AGENTS;

EID: 79958273712     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182145850     Document Type: Article

References (48)

1. Dashwood MR, Loesch A. The saphenous vein as a bypass conduit: the potential role of vascular nerves in graft performance. Curr Vasc Pharmacol. 2009;7:47-57.
2. Shuhaiber JH, Evans AN, Massad MG, et al. Mechanisms and future directions for prevention of vein graft failure in coronary bypass surgery. Eur J Cardiothorac Surg. 2002;22:387-396. (Pubitemid 36157379)
3. Raingo J, Rebolledo A, Grassi de Gende AO, et al. pH effects on high conductance Ca2+-activated K+ channels (BKCa) in human internal mammary artery smooth muscle cells. Life Sci. 2005;77:1993-2003. (Pubitemid 41080642)
4. He GW, Yang CQ, Starr A. Overview of the nature of vasoconstriction in arterial grafts for coronary operations. Ann Thorac Surg. 1995;59:676-683.
5. Liu MH, Storm Floten H, Furnary AP, et al. Effects of potassium channel opener aprikalim on the receptor-mediated vasoconstriction in the human internal mammary artery. Ann Thorac Surg. 2001;71:636-641. (Pubitemid 32173848)
6. Firmin RK, Bouloux P, Allen P, et al. Sympathoadrenal function during cardiac operations in infants with the technique of surface cooling, limited cardiopulmonary bypass, and circulatory arrest. J Thorac Cardiovasc Surg. 1985;90:729-735. (Pubitemid 16206798)
7. Deja MA, Golba KS, Malinowski M, et al. Skeletonization of internal thoracic artery affects its innervation and reactivity. Eur J Cardiothorac Surg. 2005;28:551-557. (Pubitemid 41345243)
8. Racchi H, Irarrázabal MJ, Howard M, et al. Adenosine 5-triphosphate is a co-transmitter together with neuropeptide Y and noradrenaline in the neuroeffector junction of the human saphenous vein. Br J Pharmacol. 1999;126:1175-1185. (Pubitemid 29123753)
9. Novakovic A, Bukarica Gojkovic Lj, Beleslin-Cokic B, et al. Differential antivasoconstrictor effects of levcromakalim and rilmakalim on the isolated human mammary artery and saphenous vein. J Pharmacol Sci. 2003;92:108-114. (Pubitemid 36833456)
10. Donoso MV, Miranda R, Irarrazaval MJ, et al. Neuropeptide Y is released from human mammary and radial vascular biopsies and is a functional modulator of sympathetic cotransmission. J Vasc Res. 2004;41:387-399. (Pubitemid 39541250)
11. He GW. Verapamil plus nitroglycerin solution maximally preserves endothelial function of the radial artery: comparison with papaverine solution. J Thorac Cardiovasc Surg. 1998;115:1321-1327.
12. Novella S, Martinez AC, Pagan RM, et al. Plasma levels and vascular effects of vasopressin in patients undergoing coronary artery bypass grafting. Eur J Cardiothorac Surg. 2007;32:69-76. (Pubitemid 46874987)
13. Noma A. ATP-regulated K+ channels in cardiac muscle. Nature. 1983; 305:147-148.
14. Nelson MT, Quayle JM. Physiological roles and properties of potassium channels in arterial smoothmuscle. Am J Physiol. 1995;268(pt 1):C799-C822.
15. Inagaki N, Gonoi T, Clement JP IV, et al. Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science. 1995;270:1166-1170.
16. Jahangir A, Terzic A. K(ATP) channel therapeutics at the bedside. J Mol Cell Cardiol. 2005;39:99-112.
17. Gojkovic Bukarica Lj, Kazic T, Sajic Z, et al. The effects of levcromakalim and pinacidil on the human internal mammary artery. Fundam Clin Pharmacol. 1997;11:550-560. (Pubitemid 27520919)
18. Liss B, Roper J. Molecular physiology of neuronal K-ATP channels. Mol Membr Biol. 2001;18:117-127. (Pubitemid 32666791)
19. Oe K, Sperlagh B, Santha E, et al. Modulation of norepinephrine release by ATP-dependent K+-channel activators and inhibitors in guinea-pig and human isolated right atrium. Cardiovasc Res. 1999;43:125-134. (Pubitemid 29322872)
20. Takata Y, Shimada F, Kato H. Differential effects of diazoxide, cromakalim and pinacidil on adrenergic neurotransmission and 86Rb efflux in rat brain cortical slices. J Pharmacol Exp Ther. 1992;263:1296-1301.
21. Sargent CA, Sleph PG, Dzwonczyk S, et al. Cardioprotective effects of the cyanoguanidine potassium channel opener P-1075. J Cardiovasc Pharmacol. 1993;22:564-570. (Pubitemid 23286752)
22. Mü ller CA, Markovic-Lipkovski J, Klatt T, et al. Human alpha-defensins HNPs-1, -2, and -3 in renal cell carcinoma: influences on tumor cell proliferation. Am J Pathol. 2002;160:1311-1324.
23. Shepherd JT, Vanhoutte PM. Local modulation of adrenergic neurotransmission in blood vessels. J Cardiovasc Pharmacol. 1985;7:167-178.
24. Arunlakshana O, Shild HO. Some quantitive uses of drug antagonists. Br J Pharmacol Chemother 1959;14:48-58.
25. Masuzawa K, Matsuda T, Asano M. Evidence that pinacidil may promote the opening of ATP-sensitive K+ channels yet inhibit the opening of Ca2(+)-activated K+ channels in K(+)-contracted canine mesenteric artery. Br J Pharmacol. 1990;100:143-149. (Pubitemid 20161444)
26. Weinstein J, Grossman W, Weintraub RM, et al. Differences in a-adrenergic responsiveness between human internal mammary arteries and saphenous veins. Circulation. 1989;79:1264-1270. (Pubitemid 19155761)
27. Mauricio MD, Serna E, Cortina B, et al. Role of Ca2+-activated K+ channels on adrenergic responses of human saphenous vein. Am J Hypertens. 2007;20:78-82. (Pubitemid 46014064)
28. Pagan RM, Martinez AC, Martinez MP, et al. Endothelial and potassium channel dependent modulation of noradrenergic vasoconstriction in the pig radial artery. Eur J Pharmacol. 2009;616:166-174.
29. Martinez AC, Pagain RM, Prieto D, et al. Modulation of noradrenergic neurotransmission in isolated rat radial artery. J Pharmacol Sci. 2009;111: 299-311.
30. Tan J, Al Abed A, Brock JA. Inhibition of KATP channels in the rat tail artery by neurally released noradrenaline acting on postjunctional a2- adrenoceptors. J Physiol. 2007;581:757-765. (Pubitemid 46831769)
31. Cai B, Hao Q, Greenberg SS, et al. Differential effects of pinacidil and cromakalim on vascular relaxation and sympathetic neurotransmission. Can J Physiol Pharmacol. 1994;72:801-810. (Pubitemid 24305128)
32. Gojkovic-Bukarica Lj, Kazic T. Differential effects of pinacidil and levcromakalim on the contractions elicited electrically or by noradrenaline in the portal vein of the rabbit. Fundam Clin Pharmacol. 1999;13:527-534.
33. Sun X, Cao K, Yang G, et al. Selective expression of Kir6.1 protein in different vascular and non-vascular tissues. Biochem Pharmacol. 2004;67:147-156. (Pubitemid 37518542)
34. Cui Y, Tran S, Tinker A, et al. The molecular composition of K(ATP) channels in human pulmonary artery smooth muscle cells and their modulation by growth. Am J Respir Cell Mol Biol. 2002;26:135-143. (Pubitemid 34029830)
35. Ploug KB, Sørensen MA, Strøbech L, et al. KATP channels in pig and human intracranial arteries. Eur J Pharmacol. 2008;601:43-49.
36. Jansen-Olesen I,MortensenCH,El-BariakiN, et al.Characterization ofK(ATP)- channelsin ratbasilarandmiddlecerebralarteries: studiesofvasomotor responses and mRNA expression. Eur J Pharmacol. 2005;523:109-118. (Pubitemid 41568377)
37. Morrissey A, Rosner E, Lanning J, et al. Immunolocalization of KATP channel subunits in mouse and rat cardiac myocytes and the coronary vasculature. BMC Physiol. 2005;5:1.
38. Standen NB, Quayle JM, Davies NW, et al. Hyperpolarizing vasodilatators activate ATP-sensitive channels in arterial smooth muscle. Science. 1989; 245:177-180. (Pubitemid 19193933)
39. Fabiani ME, Story DF. Prejunctional effects of cromakalim, nicorandil and pinacidil on noradrenergic transmission in rat isolated mesenteric artery. J Auton Pharmacol. 1994;14:87-98. (Pubitemid 24194762)
40. Higdon NR, Khan SA, Buchanan LV, et al. Tissue and species variation in the vascular receptor binding of 3H-P1075, a potent KATP opener vasodilator. J Pharmacol Exp Ther. 1997;280:255-260. (Pubitemid 27171410)
41. Ren Z, Floten S, Furnary A, et al. Effects of potassium channel opener KRN4884 on human conduit arteries used as coronary bypass grafts. Br J Clin Pharmacol. 2000;50:154-160. (Pubitemid 30612033)
42. Yamada M, Isomoto S, Matsumoto S, et al. Sulphonylurea receptor 2B and Kir6.1 form a sulphonylurea-sensitive but ATP-insensitive K+ channels. J Physiol (Lond). 1997;499:715-720. (Pubitemid 27153593)
43. Schotborgh C, Wilde A. Sulfonylurea derivates in cardiovascular research and in cardiovascular patients. Cardiovasc Res. 1997;34:73-80. (Pubitemid 27261915)
44. Cole WC, Clement-Chomienne O. ATP-sensitive K+ channels of vascular smooth muscle cells. J Cardiovasc Electrophysiol. 2003;14:94-103. (Pubitemid 36246731)
45. Hambrock A, Löffler-Walz C, Russ U, et al. Characterization of a mutant sulfonylurea receptor SUR2B with high affinity for sulfonylureas and openers: differences in the coupling to Kir6.x subtypes. Mol Pharmacol. 2001;60:190-199. (Pubitemid 32595247)
46. Gojkovic-Bukarica L, Savic N, Peric M, et al. Effect of potassium channel opener pinacidil on the contractions elicited electrically or by noradrenaline in the human radial artery. Eur J Pharmacol. 2011;654:266-273.
47. Miki T, Suzuki M, Shibasaki T, et al. Mouse model of Prinzmetal angina by disruption of the inward rectifier Kir6.1. Nat Med. 2002;8:466-472. (Pubitemid 34546748)
48. Terzic A, Perez-Terzic C. Channelopathies: decoding disease pathogenesis. Sci Transl Med. 2010;2:42ps37.